{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:08:52Z","timestamp":1788930532049,"version":"build-2803163510"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Breast cancer (BC) is the most commonly diagnosed malignancy among women globally and in India. The human epidermal growth factor receptor 2 (HER2)-positive subtype is associated with aggressive disease and poorer prognosis; however, neoadjuvant therapy combining dual HER2 blockade with chemotherapy has been shown to improve pathological complete response (pCR) rates. This study evaluated the real-world effectiveness of dual HER2 blockade in the Indian setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This ambispective, descriptive real-world study was conducted at KIMSHEALTH, Trivandrum, Kerala (1 October 2019\u201330 April 2025), comprising retrospective (1 October 2019\u201330 April 2024) and prospective (1 May 2024\u201330 April 2025) phases. Patients with HER2-positive early BC receiving intravenous (IV) or subcutaneous (SC) pertuzumab and trastuzumab were included. The primary endpoint was pCR. Secondary endpoints included comparison of pCR between the IV and SC groups; assessment of chemotherapy regimen, disease stage, and hormonal status on outcomes; and evaluation of treatment-related toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 74 patients (35: retrospective; 39: prospective) (mean age: 56.8\u00a0\u00b1\u00a09.1 years) were included in the study; 52 (70.3%) received SC, and 22 (29.7%) received IV dual HER2 blockade. The overall pCR rate was 51.4% (SC: 44.2%; IV: 68.2%; p=0.06). Tumor stage (p=0.044) and composite clinical stage (tumor, node, and metastasis) (p=0.019) were significantly associated with pCR in the overall population, whereas estrogen receptor (ER) status was not associated with pCR (p=0.064). Multivariate analysis identified the composite clinical stage as an independent predictor of pCR (odds ratio: 0.242; p=0.012). Anemia was the most common toxicity, followed by hepatic toxicity, with comparable safety between the SC and IV groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Neoadjuvant dual HER2 blockade in HER2-positive BC is effective and well tolerated in the Indian real-world setting, with tumor stage and composite clinical stage significantly influencing response, while ER status showed no significant association with pCR. SC and IV dual HER2 blockade demonstrated comparable efficacy and safety outcomes. These findings, which are consistent with historical data, further reinforce the therapeutic advancement from trastuzumab-based therapy to dual HER2 blockade, highlighting its improved effectiveness and clinical importance in the neoadjuvant treatment of HER2-positive BC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1895998","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:41:39Z","timestamp":1788928899000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world response rates in patients with human epidermal growth factor receptor 2-positive breast cancer after neoadjuvant treatment using dual human epidermal growth factor receptor 2 blockade"],"prefix":"10.3389","volume":"16","author":[{"given":"Abdul Shahid","family":"Poovathum Parambil","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, KIMS Health","place":["Trivandrum, Kerala, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abul Hussain","family":"Mirsa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, KIMS Health","place":["Trivandrum, Kerala, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azgar","family":"Abdul Rasheed","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, KIMS Health","place":["Trivandrum, Kerala, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Vasudevan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, KIMS Health","place":["Trivandrum, Kerala, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","unstructured":"Breast Cancer Cases and Deaths are Projected to Rise Globally\n          \n          2025"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat Med"},{"key":"B3","unstructured":"Ferlay\n              J\n            \n            \n              Ervik\n              M\n            \n            \n              Lam\n              F\n            \n            \n              Laversanne\n              M\n            \n            \n              Colombet\n              M\n            \n            \n              Mery\n              L\n            \n          \n          Global Cancer Observatory: Cancer Today\n          \n          2024"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-024-07264-3","article-title":"Burden of female breast cancer in India: estimates of YLDs, YLLs, and DALYs at national and subnational levels based on the national cancer registry programme","volume":"205","author":"Kulothungan","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"B5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4132\/jptm.2019.11.03","article-title":"HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation","volume":"54","author":"Ahn","year":"2020","journal-title":"J Pathol Transl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2023.03.007","article-title":"Risk of recurrence in patients with HER2+ early-stage breast cancer: literature analysis of patient and disease characteristics","volume":"23","author":"O\u2019Shaughnessy","year":"2023","journal-title":"Clin Breast Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-2782","article-title":"Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER database","volume":"25","author":"Hwang","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B8","unstructured":"Breast Cancer Version 4.2025\n          \n          2025"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1066007","article-title":"Review of the status of neoadjuvant therapy in HER2-positive breast cancer","volume":"13","author":"Dowling","year":"2023","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B13","unstructured":"Greenblatt\n              K\n            \n            \n              Trastuzumab\n              KK\n            \n          \n          Treasure Island (FL\n          StatPearls Publishing\n          In: Statpearls\n          \n          2024"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(09)61964-4","article-title":"Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-1268","article-title":"First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer","volume":"20","author":"Amiri-Kordestani","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx773","article-title":"Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study","volume":"29","author":"Swain","year":"2018","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2024.10.005","article-title":"A clinical review of subcutaneous trastuzumab and the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in the treatment of HER2-positive breast cancer","volume":"25","author":"Ziegengeist","year":"2025","journal-title":"Clin Breast Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2147\/bctt.s176514","article-title":"Combination of pertuzumab and trastuzumab in the treatment of HER2-positive early breast cancer: a review of the emerging clinical data","volume":"13","author":"Jagosky","year":"2021","journal-title":"Breast Cancer"},{"key":"B21","unstructured":"CDSCO Approved Drugs\/Vaccines\/R-DNA\/Blood Product"},{"key":"B22","unstructured":"Phesgo\u00ae Product Information\n          \n          2024"},{"key":"B23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/s1470-2045(20)30536-2","article-title":"Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study","volume":"22","author":"Tan","year":"2021","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/1078155221999712","article-title":"Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: a multidisciplinary approach","volume":"27","author":"DuMond","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/op.24.00021","article-title":"Subcutaneous vs intravenous trastuzumab\/pertuzumab: a time and motion substudy of a phase II trial of adjuvant trastuzumab\/pertuzumab for stage I HER2+ breast cancer (ADEPT trial","volume":"21","author":"Waks","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"B26","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3390\/curroncol32120658","article-title":"Real-world outcomes of subcutaneous PHESGO\u00ae in HER2-positive breast cancer: pathological response, sequencing, and safety","volume":"32","author":"Yanagihara","year":"2025","journal-title":"Curr Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2018-0902-sa","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"B29","volume-title":"Er (Estrogen Receptor) Total Allred Score","year":"2025"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4103\/crst.crst_197_21","article-title":"Correlation of pathological complete response with outcomes in locally advanced breast cancer treated with neoadjuvant chemotherapy: an ambispective study","volume":"4","author":"Choudhary","year":"2021","journal-title":"Cancer Research Statistics Treat"},{"key":"B31","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE\n          \n          2025"},{"key":"B32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.21873\/anticanres.17943","article-title":"Efficacy and safety of subcutaneous pertuzumab-trastuzumab (Phesgo) in neoadjuvant treatment of HER2-positive breast cancer: real-world data from Japan","volume":"46","author":"Kinoshita","year":"2026","journal-title":"Anticancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1446414","article-title":"HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future","volume":"15","author":"Xu","year":"2024","journal-title":"Front Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10549-017-4155-2","article-title":"Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients","volume":"163","author":"Goorts","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051434","article-title":"Clinical outcomes of neoadjuvant therapy in human epidermal growth factor receptor 2 breast cancer patients: a single-center retrospective study","volume":"11","author":"Hung","year":"2022","journal-title":"J Clin Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12957-024-03365-x","article-title":"Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in China","volume":"22","author":"Peng","year":"2024","journal-title":"World J Surg Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3892\/ol.2023.14021","article-title":"Predictors of successful neoadjuvant treatment in HER2 positive breast cancer","volume":"26","author":"H\u00e4nnik\u00e4inen","year":"2023","journal-title":"Oncol Lett"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-11367-w","article-title":"The effect of age on outcomes after neoadjuvant chemotherapy for breast cancer","volume":"29","author":"Verdial","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12885-024-11871-0","article-title":"Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer","volume":"24","author":"Yang","year":"2024","journal-title":"BMC Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000030892","article-title":"Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer","volume":"101","author":"Ma","year":"2022","journal-title":"Med (Baltimore"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100670","article-title":"Neoadjuvant trastuzumab and pertuzumab in combination with standard chemotherapy for HER2-positive early breast cancer: real-world practice in Cuba","volume":"34","author":"Medina","year":"2023","journal-title":"Cancer Treat Res Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0299-9","article-title":"Towards personalized treatment for early stage HER2-positive breast cancer","volume":"17","author":"Goutsouliak","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5022","article-title":"Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP","volume":"12","author":"Ji","year":"2023","journal-title":"Cancer Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1895998\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:41:45Z","timestamp":1788928905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1895998\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":44,"alternative-id":["10.3389\/fonc.2026.1895998"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1895998","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1895998"}}